Shares of Puma Biotechnology Inc (NYSE:PBYI) have earned a consensus recommendation of “Buy” from the eleven brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $115.33.

PBYI has been the topic of a number of recent research reports. Leerink Swann reaffirmed an “outperform” rating and set a $125.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, August 2nd. Zacks Investment Research lowered Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. Royal Bank Of Canada lifted their target price on Puma Biotechnology from $60.00 to $88.00 and gave the company a “sector perform” rating in a report on Tuesday, June 6th. J P Morgan Chase & Co reissued an “overweight” rating and set a $89.00 target price on shares of Puma Biotechnology in a research note on Tuesday, June 6th. Finally, Bank of America Corporation reissued a “buy” rating and set a $117.00 target price (up from $100.00) on shares of Puma Biotechnology in a research note on Friday, July 21st.

Puma Biotechnology (NYSE:PBYI) traded up 2.52% during mid-day trading on Wednesday, reaching $119.95. 326,246 shares of the company were exchanged. The stock’s 50-day moving average price is $98.26 and its 200-day moving average price is $72.59. The stock’s market capitalization is $4.46 billion. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $122.40.

Puma Biotechnology (NYSE:PBYI) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.78). On average, equities research analysts anticipate that Puma Biotechnology will post ($8.67) EPS for the current fiscal year.

In related news, SVP Richard Paul Bryce sold 1,998 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $94.48, for a total value of $188,771.04. Following the completion of the transaction, the senior vice president now directly owns 27,246 shares of the company’s stock, valued at $2,574,202.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alan H. Auerbach sold 13,175 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $94.73, for a total value of $1,248,067.75. Following the completion of the transaction, the insider now directly owns 4,170,623 shares of the company’s stock, valued at $395,083,116.79. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,173 shares of company stock worth $4,738,189. 22.70% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas purchased a new stake in shares of Puma Biotechnology during the 2nd quarter worth approximately $211,000. Renaissance Technologies LLC acquired a new position in shares of Puma Biotechnology in the 1st quarter valued at $7,682,000. American International Group Inc. boosted its holdings in shares of Puma Biotechnology by 19.2% in the 1st quarter. American International Group Inc. now owns 16,931 shares of the biopharmaceutical company’s stock valued at $630,000 after buying an additional 2,733 shares in the last quarter. Endurant Capital Management LP acquired a new position in shares of Puma Biotechnology in the 1st quarter valued at $1,101,000. Finally, Swiss National Bank boosted its holdings in shares of Puma Biotechnology by 2.1% in the 1st quarter. Swiss National Bank now owns 54,730 shares of the biopharmaceutical company’s stock valued at $2,036,000 after buying an additional 1,100 shares in the last quarter. 80.98% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Puma Biotechnology Inc (PBYI) Receives Consensus Rating of “Buy” from Analysts” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/04/puma-biotechnology-inc-pbyi-receives-consensus-rating-of-buy-from-analysts.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.